New Cousteau-Linked...
Health Care: Drugs
Achillion Pharmaceuticals Inc. (ACHN: NASDAQ)
$6.95 0.06 | 0.87%
06/04/12 - 02:38 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 16.11M | 25.37M | 9.71M | 11.06M |
| Receivables | 103.00K | 246.00K | 65.00K | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 55.09M | 57.50M | 10.54M | 36.54M |
| Property, Plant & Equipment, Gross | 6.48M | 6.37M | 7.35M | 7.56M |
| Accumulated Depreciation & Depletion | 5.49M | 5.90M | 6.48M | 5.78M |
| Property, Plant & Equipment, Net | 994.00K | 468.00K | 876.00K | 1.77M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 26.54M | 269.00K | 249.00K | 253.00K |
| Total Non-Current Assets | 27.54M | 737.00K | 1.12M | 2.02M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 82.63M | 58.24M | 11.67M | 38.56M |
| Accounts Payable | 4.80M | 2.67M | 2.28M | 2.54M |
| Short Term Debt | 141.00K | 469.00K | 2.87M | 6.25M |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 8.94M | 5.20M | 7.74M | 12.18M |
| Long Term Debt | 229.00K | 0.00 | 417.00K | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 2.49M | 2.49M | 2.49M | 1.36M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 2.72M | 2.49M | 2.91M | 1.36M |
| Total Liabilities | 11.66M | 7.69M | 10.65M | 13.54M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 70.97M | 50.54M | 1.02M | 25.02M |
| Common Par | 70.00K | 58.00K | 27.00K | 26.00K |
| Additional Paid In Capital | 346.52M | 281.88M | 206.91M | 204.86M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -275.60M | -231.39M | -205.91M | -179.98M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -20.00K | 2.00K | 0.00 | 115.00K |
| Total Capitalization | 71.20M | 50.54M | 1.44M | 25.02M |
| Total Equity | 70.97M | 50.54M | 1.02M | 25.02M |
| Total Liabilities & Stock Equity | 82.63M | 58.24M | 11.67M | 38.56M |
| Total Common Shares Outstanding | 69.79M | 58.38M | 26.71M | 26.40M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 64.25M | 45.08M | 26.54M | 19.81M |
| Diluted Weighted Shares Outstanding | 64.25M | 45.08M | 26.54M | 19.81M |
| Number of Employees | 48 | 42 | 43 | 54 |
| Number of Part-Time Employees | 2 | 2 | 0 | 0 |
Portfolios with ACHN
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- UserThe cash burners
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Hep C Stocks on Wall Str...
- Contributor10 Health-Care Stocks Outpe...
- ContributorHep C Drug Stocks in the Sp...
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
Latest ACHN Headlines from TheStreet
- Grading Hep C Stocks Exiting EASL Confab 04.23.12 | 09:04 am
- Achillion Stock Gaps Down On Today's Open (ACHN) 04.19.12 | 08:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- 8 Stocks Rising on Monster Volume 02.17.12 | 02:02 pm
- Hedge Funds Catch Hep C Fever 02.15.12 | 10:02 am
- Biotech Stock Mailbag: Vical, Hep C Drugs 01.27.12 | 07:01 am
- BioLineRx: Tuesday's Hot Hep C Drug Stock 01.24.12 | 11:01 am
- Idenix Pharma Buyout Likely: Survey 01.20.12 | 03:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- 4 Companies That Are Bleeding Cash 01.13.12 | 07:01 am
Press Releases for ACHN
- Emerald Holds Annual Groundhog Day Investment Forum - Business Wire 02.06.12 | 08:02 am
Partner Headlines for ACHN
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C - Benzinga 04.21.12 | 04:04 pm
- UPDATE: Bank of America Raises Actuant's PT - Benzinga 03.08.12 | 01:03 pm
- Gilead's Electron Data Brings Some Reality Back To The Hep C Market - Seeking Alpha 02.17.12 | 09:02 am
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Company News for January 25, 2012 - Corporate Summary - Zacks 01.25.12 | 10:01 am
- Afternoon Movers; Negative Euro News - Benzinga 01.24.12 | 04:01 pm
- Benzinga's M&A Chatter for Friday January 20, 2012 - Benzinga 01.20.12 | 06:01 pm
- End-of-Day Market Summary for January 20, 2012 - Benzinga 01.20.12 | 04:01 pm
- Afternoon Movers; Markets Moved Sideways - Benzinga 01.20.12 | 04:01 pm
- 10 Biotech Stocks With Strong Corporate Governance - Seeking Alpha 01.18.12 | 09:01 am
